利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

82 条记录 (耗时 0.028 秒)

    Cyclin dependent kinase 4 inhibitor
    1.
    发明授权
    Cyclin dependent kinase 4 inhibitor 失效
    细胞周期蛋白依赖性激酶4抑制剂

    公开(公告)号：US06689864B1

    公开(公告)日：2004-02-10

    申请号：US08921954

    申请日：1997-08-26

    申请人： Dennis A. Carson ,  Tsutomu Nobori

    发明人： Dennis A. Carson ,  Tsutomu Nobori

    IPC分类号： C07K100

    CPC分类号： C07K16/18 ,  A61K38/00 ,  C07K14/4703

    摘要： A gene that encodes an inhibitor of CDK4 has been discovered and its genomic nucleotide sequence has been identified. Susceptibility to certain cancers has been shown to be causatively related to the deletion of, or polymorphisms in, the CDK4I gene. The invention is therefore directed to the gene (CDK4I), the inhibitor protein, as well as therapeutic and diagnostic methods which utilize both the CDK4I gene and the CDK4I protein.

    摘要翻译： 已经发现了编码CDK4抑制剂的基因，并且已经鉴定了其基因组核苷酸序列。 已经显示某些癌症的易感性与CDK4I基因的缺失或多态性有关。 因此，本发明涉及基因（CDK4I），抑制剂蛋白质，以及利用CDK4I基因和CDK4I蛋白质的治疗和诊断方法。

    Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
    2.
    发明授权
    Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment 失效
    肿瘤抑制基因和癌症检测方法，肿瘤进展监测和癌症治疗

    公开(公告)号：US06689561B1

    公开(公告)日：2004-02-10

    申请号：US08227800

    申请日：1994-04-14

    申请人： Dennis A. Carson ,  Tsutomu Nobori

    发明人： Dennis A. Carson ,  Tsutomu Nobori

    IPC分类号： C12Q168

    CPC分类号： C07K14/4703 ,  A61K38/00 ,  C07K16/18

    摘要： A gene that encodes an inhibitor of CDK4 has been discovered and its genomic nucleotide sequence has been identified. Susceptibility to certain cancers has been shown to be causatively related to the deletion of, or polymorphisms in, the CDK4I gene. The invention is therefore directed to the gene (CDK4I), the inhibitor protein, as well as therapeutic and diagnostic methods which utilize both the CDK4I gene and the CDK4I protein.

    摘要翻译： 已经发现了编码CDK4抑制剂的基因，并且已经鉴定了其基因组核苷酸序列。 已经显示某些癌症的易感性与CDK4I基因的缺失或多态性有关。 因此，本发明涉及基因（CDK4I），抑制剂蛋白质，以及利用CDK4I基因和CDK4I蛋白质的治疗和诊断方法。

    Method for inhibiting adenylosuccinate synthetase activity in malignant methylthioadenosine phosphorylase deficient cells
    4.
    发明授权
    Method for inhibiting adenylosuccinate synthetase activity in malignant methylthioadenosine phosphorylase deficient cells 失效
    恶性甲基硫代腺苷磷酸化酶缺陷型细胞中腺苷酸琥珀酸合成酶抑制活性的方法

    公开(公告)号：US06214571B1

    公开(公告)日：2001-04-10

    申请号：US09199137

    申请日：1998-11-24

    申请人： Carlos J. Carrera ,  Dennis A. Carson ,  Howard B. Cottam ,  Tsutomu Nobori

    发明人： Carlos J. Carrera ,  Dennis A. Carson ,  Howard B. Cottam ,  Tsutomu Nobori

    IPC分类号： C12Q134

    CPC分类号： C12Q1/6886 ,  A61K31/198 ,  C12N9/1077

    摘要： An in vivo method for depleting mammalian cells of adenosine 5′-monophosphate (AMP) useful in the treatment of certain cancers is provided. According to the method, a population of cells is obtained from a host and assayed for loss of methylthioadenosine phosphorylase (MTAse) activity. MTAse catabolizes methylthioadenosine to adenine for endogenous salvage incorporation into the intracellular AMP pool. The preferred method for assaying loss of MTAse activity is a hybridization technique for detection of a homozygous loss of the gene which encodes MTAse. Hosts having MTAse deficient tumors are treated with a therapeutically effective amount of an agent which inhibits the activity of adenylsuccinate synthetase, which converts inosine 5-monophosphate to AMP, thus depleting the tumor cells of substrates for de novo AMP production. L-alanosine is the preferred ASS inhibitory agent for use in the method of the invention.

    摘要翻译： 提供了用于消除用于治疗某些癌症的腺苷5'-单磷酸（AMP）的哺乳动物细胞的体内方法。 根据该方法，从宿主获得细胞群并测定甲硫基腺苷磷酸化酶（MTAse）活性的损失。 MTAs将甲基硫代腺苷分解为腺嘌呤，用于内源性补救并入细胞内AMP库。 用于测定MTAse活性丧失的优选方法是用于检测编码MTAse的基因的纯合丢失的杂交技术。 具有MTAse缺陷肿瘤的宿主用治疗有效量的抑制腺苷酸琥珀酸合成酶活性的药物进行治疗，其将5-单磷酸肌苷转化为AMP，从而消耗底物的肿瘤细胞用于从头AMP产生。 L-肌氨酸是用于本发明方法的优选的ASS抑制剂。

    Method for selective methionine starvation of malignant cells in mammals
    6.
    发明授权
    Method for selective methionine starvation of malignant cells in mammals 失效
    哺乳动物恶性细胞选择性甲硫氨酸饥饿的方法

    公开(公告)号：US5571510A

    公开(公告)日：1996-11-05

    申请号：US176413

    申请日：1993-12-29

    申请人： Tsutomu Nobori ,  Dennis A. Carson

    发明人： Tsutomu Nobori ,  Dennis A. Carson

    IPC分类号： C12N15/09 ,  A61K38/00 ,  A61K38/46 ,  A61K38/51 ,  A61K47/48 ,  A61P35/00 ,  C07H21/04 ,  C12N9/88 ,  C12N15/00 ,  C12N15/60 ,  C12Q1/48 ,  C12Q1/527 ,  C12Q1/68 ,  C12R1/19 ,  C12R1/40 ,  G01N33/573

    CPC分类号： A61K47/48215 ,  A61K38/51 ,  C12N9/88 ,  C12Q1/527

    摘要： An improved method for chemotherapy of mammalian malignant cells which have an absolute requirement for methionine but lack methylthioadenosine phosphorylase (MTAse). The method comprises detection of MTAse negative cells in a mammal, administration of methionine .gamma.-lyase in sufficient amounts to reduce the volume of MTAse negative cells in the mammal, and co-administration of methylthioadenosine in amounts sufficient to ensure the continued availability of methionine to the mammal's non-malignant cells. Means for detection of MTAse negative cells are provided. Means for production and use of recombinant chemotherapeutic agents are also provided.

    摘要翻译： 一种改进的哺乳动物恶性细胞化疗方法，对蛋氨酸具有绝对要求但缺乏甲硫基腺苷磷酸化酶（MTAse）。 该方法包括检测哺乳动物中MTAs阴性细胞，以足够量的量施用甲硫氨酸γ-裂解酶以减少哺乳动物中MTAs阴性细胞的体积，并以足以确保甲硫氨酸持续可用性的量共同给予甲硫基腺苷 哺乳动物的非恶性细胞。 提供了检测MTA阴性细胞的方法。 还提供了生产和使用重组化学治疗剂的方法。

    Use of etodolac to treat hyperplasia
    10.
    发明授权
    Use of etodolac to treat hyperplasia 失效

    公开(公告)号：US07211599B2

    公开(公告)日：2007-05-01

    申请号：US10667208

    申请日：2003-09-19

    申请人： Dennis A. Carson ,  Lorenzo M. Leoni ,  Mary Patricia Corr

    发明人： Dennis A. Carson ,  Lorenzo M. Leoni ,  Mary Patricia Corr

    IPC分类号： A61K31/40 ,  A61K31/56 ,  A61K31/50 ,  A61K31/18 ,  A61K31/12

    CPC分类号： A61K31/12 ,  A61K31/18 ,  A61K31/40 ,  A61K31/407 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/50 ,  A61K31/56 ,  A61K31/675 ,  A61K31/7052

    摘要： The present invention provides a therapeutic method to treat non-malignant diseases characterized by the excessive tissue growth, e.g., hyperplastic diseases, comprising administering to a mammal (e.g., human) afflicted with excessive tissue growth, an effective amount of a derivative of an indole compound of formula (I):formula (I): wherein R1 is lower alkyl, (hydroxy)lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, phenyl, benzyl or 2-thienyl; R2, R3, R4 and R5 are the same or different and are each hydrogen or lower alkyl; each R6 is individually hydrogen, lower alkyl, hydroxy, (hydroxy)lower alkyl, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro or halo, R7 is hydrogen, lower alkyl or lower alkenyl, X is oxy and thio, Y is carbonyl, —(CH2)1-3—, —(C1-C3)alkyl(CO)—, or —(CH2)1-3SO2—; Z is hydroxy, lower alkoxy, (C2-C4)acyloxy, —N(R8)(R9), phenylamino, (ω-(4-pyridyl)(C2-C4 alkoxy), (ω-((R8)(R9)amino)(C2-C4 alkoxy), an amino acid ester of (ω-(HO)(C2-C4))alkoxy, —N(R8)CH(R8)CO2H, 1′-D-glucuronyloxy, —SO3H, —PO4H2, —N(NO)(OH), —SO2NH2, —PO(OH)(NH2), —OCH2CH2N(CH3)3+, or tetrazolyl; wherein R8 and R9 are each H, (C1-C3)alkyl or together with N are a 5- or 6-membered heterocyclic ring comprising 1-3 N(R8), S or nonperoxide O; n is 0, 1, 2, or 3; wherein R8 and R9 are each H, (C1-C3)alkyl or together with N are a 5- or 6-membered heterocyclic ring comprising 1-3 N(R8), S or nonperoxide O; each alkyl or phenyl group of R1, R2, R3, R4, R5, R6, R7 and Z is optionally substituted with 1, 2, or 3 (C1-C4)alkyl groups; or a pharmaceutically acceptable salt thereof.